Robert Krug, M.D., president and medical director of Mount Sinai Rehabilitation Hospital recently became the board chair for the American Medical Rehabilitation Providers Association (AMRPA).
Robert Krug M.D. Is AMRPA’s New Board Chair

AMRPA’s vision is to transform lives through access to the highest quality of medical rehabilitation care. A part of Krug’s goals this year is a focus on the patient and the services offered by medical rehabilitation providers and inpatient rehabilitation facilities (IRFs).
He will also help advance the field of medical rehabilitation through advocacy, education and the promotion of access to care.
Krug said in a statement, “IRFs play an important role not just acutely during patients’ inpatient course but also in helping individuals return to activities they love while promoting community reintegration, fitness and wellness. It’s all about a continuum and sustainability of the outcomes.”
Kruger is also the chief physician for rehabilitation medicine at Saint Francis Hospital and medical director for Physical Medicine & Rehabilitation Services at the Mandell Center for Multiple Sclerosis in Hartford, Connecticut.
John Ferraro, AMRPA executive director, said, “In Dr. Krug’s time as vice chairman of AMRPA’s Board of Directors, he contributed greatly to our association’s goals, setting new standards of excellence and innovating along the way. We have no doubt that as chairman he will perform his duties with this same level of commitment and exceed our expectations of someone befitting this important position.”
AMRPA is the only trade organization in the U.S. dedicated to the interests of inpatient rehabilitation. The association represents more than 650 rehabilitation hospitals and rehabilitation units of general hospitals.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.